These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36533948)

  • 1. Antigenic Landscape Analysis of Individuals Vaccinated with a Universal Influenza Virus Vaccine Candidate Reveals Induction of Cross-Subtype Immunity.
    Meade P; Strohmeier S; Bermúdez-González MC; García-Sastre A; Palese P; Simon V; Krammer F
    J Virol; 2023 Jan; 97(1):e0107022. PubMed ID: 36533948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial.
    Bernstein DI; Guptill J; Naficy A; Nachbagauer R; Berlanda-Scorza F; Feser J; Wilson PC; Solórzano A; Van der Wielen M; Walter EB; Albrecht RA; Buschle KN; Chen YQ; Claeys C; Dickey M; Dugan HL; Ermler ME; Freeman D; Gao M; Gast C; Guthmiller JJ; Hai R; Henry C; Lan LY; McNeal M; Palm AE; Shaw DG; Stamper CT; Sun W; Sutton V; Tepora ME; Wahid R; Wenzel H; Wohlbold TJ; Innis BL; García-Sastre A; Palese P; Krammer F
    Lancet Infect Dis; 2020 Jan; 20(1):80-91. PubMed ID: 31630990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoprotein.
    Bliss CM; Nachbagauer R; Mariottini C; Cuevas F; Feser J; Naficy A; Bernstein DI; Guptill J; Walter EB; Berlanda-Scorza F; Innis BL; García-Sastre A; Palese P; Krammer F; Coughlan L
    EBioMedicine; 2024 Jun; 104():105153. PubMed ID: 38805853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain.
    Krammer F; Palese P
    J Infect Dis; 2019 Apr; 219(Suppl_1):S62-S67. PubMed ID: 30715353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric Hemagglutinin-Based Influenza Virus Vaccines Induce Protective Stalk-Specific Humoral Immunity and Cellular Responses in Mice.
    Choi A; Bouzya B; Cortés Franco KD; Stadlbauer D; Rajabhathor A; Rouxel RN; Mainil R; Van der Wielen M; Palese P; García-Sastre A; Innis BL; Krammer F; Schotsaert M; Mallett CP; Nachbagauer R
    Immunohorizons; 2019 Apr; 3(4):133-148. PubMed ID: 31032479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Greater Breadth of Vaccine-Induced Immunity in Females than Males Is Mediated by Increased Antibody Diversity in Germinal Center B Cells.
    Ursin RL; Dhakal S; Liu H; Jayaraman S; Park HS; Powell HR; Sherer ML; Littlefield KE; Fink AL; Ma Z; Mueller AL; Chen AP; Seddu K; Woldetsadik YA; Gearhart PJ; Larman HB; Maul RW; Pekosz A; Klein SL
    mBio; 2022 Aug; 13(4):e0183922. PubMed ID: 35856618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza Virus Infection Induces a Narrow Antibody Response in Children but a Broad Recall Response in Adults.
    Meade P; Kuan G; Strohmeier S; Maier HE; Amanat F; Balmaseda A; Ito K; Kirkpatrick E; Javier A; Gresh L; Nachbagauer R; Gordon A; Krammer F
    mBio; 2020 Jan; 11(1):. PubMed ID: 31964741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies elicited in humans upon chimeric hemagglutinin-based influenza virus vaccination confer FcγR-dependent protection in vivo.
    Edgar JE; Trezise S; Anthony RM; Krammer F; Palese P; Ravetch JV; Bournazos S
    Proc Natl Acad Sci U S A; 2023 Oct; 120(44):e2314905120. PubMed ID: 37871218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice.
    Puente-Massaguer E; Vasilev K; Beyer A; Loganathan M; Francis B; Scherm MJ; Arunkumar GA; González-Domínguez I; Zhu X; Wilson IA; Coughlan L; Sun W; Palese P; Krammer F
    Sci Adv; 2023 Sep; 9(37):eadi4753. PubMed ID: 37703367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Universal influenza virus vaccines and therapeutic antibodies.
    Nachbagauer R; Krammer F
    Clin Microbiol Infect; 2017 Apr; 23(4):222-228. PubMed ID: 28216325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of adjuvant: Trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus.
    Myers ML; Gallagher JR; Woolfork DD; Stradtmann-Carvalho RK; Maldonado-Puga S; Bock KW; Boyoglu-Barnum S; Syeda H; Creanga A; Alves DA; Kanekiyo M; Harris AK
    Front Immunol; 2022; 13():1002286. PubMed ID: 36248851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines.
    Lim CML; Komarasamy TV; Adnan NAAB; Radhakrishnan AK; Balasubramaniam VRMT
    Influenza Other Respir Viruses; 2024 Mar; 18(3):e13276. PubMed ID: 38513364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct Functional Humoral Immune Responses Are Induced after Live Attenuated and Inactivated Seasonal Influenza Vaccination.
    Tong X; Deng Y; Cizmeci D; Fontana L; Carlock MA; Hanley HB; McNamara RP; Lingwood D; Ross TM; Alter G
    J Immunol; 2024 Jan; 212(1):24-34. PubMed ID: 37975667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes.
    Khan S; Jain A; Taghavian O; Nakajima R; Jasinskas A; Supnet M; Felgner J; Davies J; de Assis RR; Jan S; Obiero J; Strahsburger E; Pone EJ; Liang L; Davies DH; Felgner PL
    J Vis Exp; 2019 Jul; (149):. PubMed ID: 31403629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infant Antibody Repertoires during the First Two Years of Influenza Vaccination.
    Kuraoka M; Curtis NC; Watanabe A; Tanno H; Shin S; Ye K; Macdonald E; Lavidor O; Kong S; Von Holle T; Windsor I; Ippolito GC; Georgiou G; Walter EB; Kelsoe G; Harrison SC; Moody MA; Bajic G; Lee J
    mBio; 2022 Dec; 13(6):e0254622. PubMed ID: 36314798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained delivery of CpG oligodeoxynucleotide by acetalated dextran microparticles augments effector response to Computationally Optimized Broadly Reactive Antigen (COBRA) influenza hemagglutinin.
    Batty CJ; Amouzougan EA; A Carlock M; Ross TM; Bachelder EM; Ainslie KM
    Int J Pharm; 2023 Jan; 630():122429. PubMed ID: 36436743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allelic polymorphism controls autoreactivity and vaccine elicitation of human broadly neutralizing antibodies against influenza virus.
    Sangesland M; Torrents de la Peña A; Boyoglu-Barnum S; Ronsard L; Mohamed FAN; Moreno TB; Barnes RM; Rohrer D; Lonberg N; Ghebremichael M; Kanekiyo M; Ward A; Lingwood D
    Immunity; 2022 Sep; 55(9):1693-1709.e8. PubMed ID: 35952670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Group 1 and group 2 hemagglutinin stalk antibody response according to age.
    Sánchez-de Prada L; Sanz-Muñoz I; Sun W; Palese P; Ortiz de Lejarazu R; Eiros JM; García-Sastre A; Aydillo T
    Front Immunol; 2023; 14():1194073. PubMed ID: 37313413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of non-neutralizing human monoclonal antibodies that target the M1 and NP of influenza A viruses.
    Rijnink WF; Stadlbauer D; Puente-Massaguer E; Okba NMA; Kirkpatrick Roubidoux E; Strohmeier S; Mudd PA; Schmitz A; Ellebedy A; McMahon M; Krammer F
    J Virol; 2023 Nov; 97(11):e0164622. PubMed ID: 37916834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Host Factors Impact Vaccine Efficacy: Implications for Seasonal and Universal Influenza Vaccine Programs.
    Dhakal S; Klein SL
    J Virol; 2019 Nov; 93(21):. PubMed ID: 31391269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.